Relay Therapeutics Inc RLAY.OQ RLAY.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Cambridge Massachusetts-based company is expected to report revenue of $60 thousand, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Relay Therapeutics Inc is for a loss of 49 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Relay Therapeutics Inc is $14.00, about 73.9% above its last closing price of $3.65
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.49 | -0.49 | -0.46 | Beat | 5.7 |
Dec. 31 2025 | -0.56 | -0.56 | -0.45 | Beat | 19.9 |
Sep. 30 2024 | -0.76 | -0.77 | -0.63 | Beat | 17.9 |
Jun. 30 2024 | -0.73 | -0.73 | -0.69 | Beat | 5.8 |
Mar. 31 2024 | -0.69 | -0.70 | -0.62 | Beat | 12 |
Dec. 31 2023 | -0.69 | -0.73 | -0.67 | Beat | 8 |
Sep. 30 2023 | -0.82 | -0.83 | -0.54 | Beat | 35 |
Jun. 30 2023 | -0.84 | -0.82 | -0.81 | Beat | 0.7 |
This summary was machine generated August 5 at 20:59 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)